Business Context and Reporting Period
Company: ADC Therapeutics SA
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2026
Reporting Period: Preliminary results for the quarter and year ended December 31, 2025.
This filing serves as a Regulation FD disclosure regarding preliminary revenue estimates and cash positions. The data is unaudited and based on management's complex and subjective judgments.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing specific figures but does not explicitly state the numerical values within the text of this 8-K summary.
- Revenue: Preliminary estimates for Q4 and full-year 2025 are referenced but not disclosed in this text.
- Cash and Cash Equivalents: Preliminary balance as of December 31, 2025, is referenced but not disclosed in this text.
- Profit, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The filing text does not provide specific comparative data or percentage changes versus prior periods. It notes that actual financial results have not been finalized and may differ materially from these preliminary estimates.
Guidance, Outlook, and Risks
Management Commentary: Management emphasizes that the reported figures are preliminary and unaudited. Significant estimates and judgments were applied in preparing this information.
Risks and Contingencies:
- Accuracy Risk: Subsequent information or events may lead to material differences between these preliminary results and final audited reports.
- Reliance Warning: Investors are explicitly advised not to place undue reliance on these preliminary financial results.
- Legal Status: The information is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific revenue and cash figures in the attached Press Release (Exhibit 99.1), as they are not listed in the 8-K body text.
- Monitor the upcoming audited financial statements (10-K) for final confirmation of 2025 results.
- Assess the potential for material adjustments between these preliminary estimates and the final audited numbers.
- Confirm the company's liquidity position once the final cash balance is audited.